Key result
Low-molecular-weight heparins offer clinical and practical advantages over unfractionated heparin for managing thromboembolic disease in pregnancy, including improved safety.
Why the study?
Does low-molecular-weight heparin improve safety and prevent venous thromboembolism compared to unfractionated heparin in pregnant women?
Does low-molecular-weight heparin improve safety and prevent venous thromboembolism compared to unfractionated heparin in pregnant women?
LMWHs are preferred over unfractionated heparin for managing thromboembolic risk in pregnancy due to improved safety and practical advantages, though optimal treatment protocols remain undefined.
No takes yet. Share an insight, caveat, or question.
Supports LMWH preference in pregnancy; leaves optimal dosing and duration protocols undefined.
Ian A. Greer (2002) conducted a review in Venous thromboembolism in pregnancy. Low-molecular-weight heparin (LMWH) vs. Unfractionated heparin was evaluated. Low-molecular-weight heparins offer clinical and practical advantages over unfractionated heparin for managing thromboembolic disease in pregnancy, including improved safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: